AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36433884 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT) as an add-on to regular inpatient treatment, involving two pretreatment training sessions and eight biweekly sessions.
Number of subjects: 154
Study 36433884 — intervention group
Group type: COMPARATOR
Intervention: Non-ABMT intervention control condition
Number of subjects: 154
Study 33618522 — intervention group
Group type: EXPERIMENTAL
Intervention: HART (preoperative hyperfractionated radiotherapy)
Number of subjects: 136
Study 33618522 — intervention group
Group type: COMPARATOR
Intervention: HART-CT (concomitant hyperfractionated radiotherapy with chemotherapy)
Number of subjects: 136
Study 33618522 — intervention group
Group type: EXPERIMENTAL
Intervention: HART
Number of subjects: 136
Study 33004383 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐PARS (coproduced PA referral scheme)
Number of subjects: 68
Study 33004383 — intervention group
Group type: COMPARATOR
Intervention: Usual care ERS
Number of subjects: 68
Study 33004383 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 68
Study 34632875 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 138
Study 34632875 — intervention group
Group type: COMPARATOR
Intervention: Control TSST
Number of subjects: 138
Study 34159560 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 500 mcg od
Number of subjects: 5522
Study 34159560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522
Study 34432169 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 114
Study 32359668 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim Methadone with Patient Navigation (IM + PN)
Number of subjects: 212
Study 32359668 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim Methadone without Patient Navigation (IM)
Number of subjects: 212
Study 32359668 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment-as-Usual (ETAU)
Number of subjects: 212
Study 35029292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid plus standard medical care
Number of subjects: 36
Study 35029292 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard medical care
Number of subjects: 36
Study 32880057 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal-left PFC tDCS plus placebo medication
Number of subjects: 51
Study 32880057 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg/day for 3 weeks and 20 mg/day thereafter plus sham tDCS
Number of subjects: 51
Study 32880057 — intervention group
Group type: COMPARATOR
Intervention: placebo medication plus sham tDCS
Number of subjects: 51
Study 33427822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ananya program implemented in eight intervention districts.
Number of subjects: 8
Study 33427822 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm comprised of the remaining 30 districts in Bihar where Ananya interventions were not implemented.
Number of subjects: 8
Study 33427822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's behaviours in contraceptive utilisation.
Number of subjects: 8
Study 32243492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 200 mg single dose
Number of subjects: 6068
Study 32243492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg single dose
Number of subjects: 6068
Study 32243492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 500 mg single dose
Number of subjects: 6068
Study 32243492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 100 mg double dose
Number of subjects: 6068
Study 32243492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 200 mg double dose
Number of subjects: 6068
Study 32243492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg double dose
Number of subjects: 6068
Study 32243492 — intervention group
Group type: COMPARATOR
Intervention: Placebo single dose
Number of subjects: 6068
Study 32243492 — intervention group
Group type: COMPARATOR
Intervention: Placebo double dose
Number of subjects: 6068
Study 32243492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (all dosing regimens)
Number of subjects: 6068
Study 33892624 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure time physical activities (LTPA)
Number of subjects: 436
Study 33892624 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening
Number of subjects: 436
Study 33892624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 436
Study 33892624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility training
Number of subjects: 436
Study 33892624 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 436
Study 33892624 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairments in activities of daily living
Number of subjects: 436
Study 33892624 — intervention group
Group type: EXPERIMENTAL
Intervention: Living environment
Number of subjects: 436
Study 32928607 — intervention group
Group type: EXPERIMENTAL
Intervention: BISCPM (Brain Injury State Clinical Prediction Model)
Number of subjects: 1156
Study 32928607 — intervention group
Group type: EXPERIMENTAL
Intervention: BISCPM
Number of subjects: 1156
Study 32772618 — intervention group
Group type: EXPERIMENTAL
Intervention: h-COR test
Number of subjects: 39
Study 32772618 — intervention group
Group type: EXPERIMENTAL
Intervention: n-COR test
Number of subjects: 39
Study 32772618 — intervention group
Group type: COMPARATOR
Intervention: Group B (without oscillopsia)
Number of subjects: 39
Study 35304647 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted tidal volume of 4 ml/kg
Number of subjects: 9
Study 35304647 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted tidal volume of 5 ml/kg
Number of subjects: 9
Study 35304647 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted tidal volume of 6 ml/kg
Number of subjects: 9
Study 32960408 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus panitumumab (Pani)
Number of subjects: 101
Study 32960408 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab (Bev)
Number of subjects: 101
Study 34286472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D
Number of subjects: 31
Study 34286472 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D
Number of subjects: 31
Study 33581798 — intervention group
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Number of subjects: 200
Study 33581798 — intervention group
Group type: COMPARATOR
Intervention: cabazitaxel
Number of subjects: 200
Study 34517768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0
Study 32380119 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-Heated Tobacco Product (CHTP)
Number of subjects: 120
Study 32380119 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes
Number of subjects: 120
Study 33722330 — intervention group
Group type: EXPERIMENTAL
Intervention: Starter feed supplemented with 3% soyabean oil (SBO)
Number of subjects: 40
Study 33722330 — intervention group
Group type: EXPERIMENTAL
Intervention: Starter feed supplemented with 3% fish oil (FO)
Number of subjects: 40
Study 33722330 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal mixture of SBO and FO (1.5% each, DM basis)
Number of subjects: 40
Study 33722330 — intervention group
Group type: COMPARATOR
Intervention: Starter feed with no fat source (CON)
Number of subjects: 40
Study 33830960 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended intervals despite residual subretinal fluid (rSRF)
Number of subjects: 98
Study 33371148 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NAE therapy (n=20)
Number of subjects: 37
Study 33371148 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n=17)
Number of subjects: 37
Study 35714891 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular Quality of Life Questionnaire (VascQOL)
Number of subjects: 1830
Study 35714891 — intervention group
Group type: EXPERIMENTAL
Intervention: European Quality of Life 5D (EQ-5D)
Number of subjects: 1830
Study 35714891 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form 12 (SF-12)
Number of subjects: 1830
Study 34979631 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.3 mg/kg IV ketamine and 40.0 mg IV parecoxib (group K-P)
Number of subjects: 48
Study 34979631 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg/kg IV ketamine alone (group K)
Number of subjects: 48
Study 35580635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (10 L per minute by simple, tight‐fitting face mask until delivery)
Number of subjects: 140
Study 35580635 — intervention group
Group type: COMPARATOR
Intervention: Room air (without a face mask)
Number of subjects: 140
Study 32826635 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 105
Study 32826635 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training with Blood Flow Restriction (RT + BFR)
Number of subjects: 105
Study 32826635 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 105
Study 32826635 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte Chemoattractant Protein 1
Number of subjects: 105
Study 37659086 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 360
Study 37659086 — intervention group
Group type: COMPARATOR
Intervention: Active control (self-help manual)
Number of subjects: 360
Study 33609057 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil injection (test product)
Number of subjects: 24
Study 33609057 — intervention group
Group type: COMPARATOR
Intervention: ROPION (reference drug)
Number of subjects: 24
Study 32553489 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced bathing and decolonization
Number of subjects: 1400
Study 32553489 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1400
Study 35109780 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 15
Study 35109780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 32032804 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive gesture intervention (watching movies with intensive use of gesture)
Number of subjects: 3
Study 32032804 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gesture intervention (Visual Action Therapy)
Number of subjects: 3
Study 32032804 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3
Study 35063214 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement (1000 IU + 25 g canola oil daily, n=31)
Number of subjects: 93
Study 35063214 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D fortified oil (placebo tablet + 25 g canola oil fortified with 1000 IU vitamin D daily, n=30)
Number of subjects: 93
Study 35063214 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo tablet + 25 g canola oil, n=32)
Number of subjects: 93
Study 34175968 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine in normal saline (1:100,000)
Number of subjects: 50
Study 34175968 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 34882076 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg and valsartan 160 mg in the morning (Group 1)
Number of subjects: 174
Study 34882076 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg in the morning and valsartan 160 mg in the evening (Group 2)
Number of subjects: 174
Study 34882076 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg in the morning and valsartan 80 mg in the morning and evening (Group 3)
Number of subjects: 174
Study 33853650 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) performed by a credentialled practitioner
Number of subjects: 112
Study 33853650 — intervention group
Group type: COMPARATOR
Intervention: X-ray imaging
Number of subjects: 112
Study 33853650 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 112
Study 35459688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based supportive therapy (MBST)
Number of subjects: 73
Study 35459688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 33971616 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 13
Study 33971616 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist insights
Number of subjects: 13
Study 32750921 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockchain-enabled contextual online learning model under local differential privacy
Number of subjects: 0
Study 33107050 — intervention group
Group type: EXPERIMENTAL
Intervention: Common treatment area (owner absent)
Number of subjects: 44
Study 33107050 — intervention group
Group type: COMPARATOR
Intervention: Isolated exam room (owner present)
Number of subjects: 44
Study 35341011 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50
Study 35341011 — intervention group
Group type: COMPARATOR
Intervention: Common postoperative treatment
Number of subjects: 50
Study 33856748 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) screening tests such as CancerSEEK or GRAIL
Number of subjects: 0
Study 33856748 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) screening tests
Number of subjects: 0
Study 33856748 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 0
Study 32619240 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-h split sleep
Number of subjects: 111
Study 32619240 — intervention group
Group type: COMPARATOR
Intervention: 8-h continuous sleep
Number of subjects: 111
Study 32619240 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5-h split sleep
Number of subjects: 111
Study 32619240 — intervention group
Group type: COMPARATOR
Intervention: 6.5-h continuous sleep
Number of subjects: 111
Study 35607710 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid prophylaxis at 6 weeks of age
Number of subjects: 100
Study 35607710 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 34310883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear periodisation (NLP)
Number of subjects: 30
Study 34310883 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear periodisation (LP)
Number of subjects: 30
Study 32427934 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical current steering (vCS)
Number of subjects: 7
Study 32427934 — intervention group
Group type: COMPARATOR
Intervention: Single-contact stimulation
Number of subjects: 7
Study 36079725 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley consumption for 4 weeks
Number of subjects: 0
Study 36079725 — intervention group
Group type: COMPARATOR
Intervention: Control food for 4 weeks
Number of subjects: 0
Study 33168398 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 100000
Study 33168398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 100000
Study 33168398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephroureterectomy (NU) alone
Number of subjects: 100000
Study 32719254 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant boost radiotherapy (CBRT) - 45 Gy/25#/5-weeks and 18 Gy/10# concomitant boost in the last 2-weeks, total dose 63 Gy.
Number of subjects: 90
Study 32719254 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant boost with concurrent chemoradiation (CBRT + CCT) - CBRT with cisplatin 75 mg/m2 on day 1, 17, and 34.
Number of subjects: 90
Study 32719254 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation chemoradiation with concomitant chemotherapy (CFRT + CCT) - 64 Gy/32#/6.2 weeks, concurrent with cisplatin 75 mg/m2 on day 1, 22, and 42.
Number of subjects: 90
Study 35473743 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous energy restriction
Number of subjects: 0
Study 35473743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (5:2D)
Number of subjects: 0
Study 35473743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (5:2N)
Number of subjects: 0
Study 35473743 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34410341 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 512
Study 32371433 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at Weeks 0/2/4, then 200 mg every 2 weeks up to 96 weeks
Number of subjects: 89
Study 35815022 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAM intervention (10-week program including weekly videos, activities based on Unified Protocol therapy modules, telehealth group sessions, and online support forum)
Number of subjects: 65
Study 35815022 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) control group
Number of subjects: 65
Study 35083557 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 12.5 mg (1 mL) added to 0.5% 10 mg (2 mL) of hyperbaric bupivacaine
Number of subjects: 60
Study 35083557 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 5 μg (1 mL) added to 0.5% 10 mg (2 mL) of hyperbaric bupivacaine
Number of subjects: 60
Study 35083557 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil group
Number of subjects: 60
Study 35083557 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine group
Number of subjects: 60
Study 35083557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 34911073 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffalo Concussion Treadmill Test (BCTT)
Number of subjects: 20
Study 34911073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling test of exertion
Number of subjects: 20
Study 34911073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests
Number of subjects: 20
Study 32421401 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg)
Number of subjects: 160
Study 32421401 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (10 IU)
Number of subjects: 160
Study 36163869 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib (160 mg twice daily)
Number of subjects: 415
Study 36163869 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib (420 mg once daily)
Number of subjects: 415
Study 36163869 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 415
Study 36163869 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 415
Study 34043412 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin (CAPOX) followed by concurrent radiation and capecitabine (CAPRT)
Number of subjects: 301
Study 34043412 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin (CAPOX)
Number of subjects: 301
Study 32991110 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral citrulline supplementation
Number of subjects: 16
Study 32991110 — intervention group
Group type: COMPARATOR
Intervention: Control group without citrulline supplementation
Number of subjects: 16
Study 36129535 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (30–60 s)
Number of subjects: 64
Study 36129535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut cord milking (C-UCM) (20–30 cm)
Number of subjects: 64
Study 36129535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact cord milking (I-UCM) (3–4 strippings)
Number of subjects: 64
Study 36129535 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 33231879 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 49
Study 33231879 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive chemotherapy (SC)
Number of subjects: 49
Study 36136826 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific practice (training on one form of a task)
Number of subjects: 0
Study 36136826 — intervention group
Group type: COMPARATOR
Intervention: Varied practice (training on various forms of a task)
Number of subjects: 0
Study 36136826 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific practice
Number of subjects: 0
Study 36136826 — intervention group
Group type: COMPARATOR
Intervention: Varied practice
Number of subjects: 0
Study 34187081 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes (EC)
Number of subjects: 135
Study 34187081 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Treatment (NRT)
Number of subjects: 135
Study 33217770 — intervention group
Group type: EXPERIMENTAL
Intervention: Air polishing followed by scaling (AS)
Number of subjects: 173
Study 33217770 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling followed by air polishing (SA)
Number of subjects: 173
Study 33217770 — intervention group
Group type: COMPARATOR
Intervention: Scaling followed by rubber cup polishing (SR)
Number of subjects: 173
Study 34872748 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study 34872748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34485877 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite 100 mcg/day
Number of subjects: 66
Study 34485877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 36008062 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychoeducational intervention integrating dialectical behavioural therapy and empowerment approach
Number of subjects: 86
Study 36008062 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 86
Study 32896291 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd26-S (one dose)
Number of subjects: 76
Study 32896291 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd5-S (one dose)
Number of subjects: 76
Study 32896291 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd26-S and rAd5-S (prime-boost vaccination)
Number of subjects: 76
Study 32896291 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen formulation
Number of subjects: 76
Study 32896291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilised formulation
Number of subjects: 76